Patent Application
20180344854
The present invention relates to supersaturated aqueous solutions of benzimidazole compounds and their use as antihistamine and antiallergic compositions. The invention also relates to the use of organic carboxylic acids to increase the aqueous solubility of benzimidazole compounds.
It has long been known that histamine plays a very important role in allergic-type diseases, such as allergic rhinitis, conjunctivitis, rhinoconjunctivitis, dermatitis, urticaria and asthma. Antihistaminic compounds acting at the H1-receptor histamine level are useful for treating such conditions.
Documents EP 0818454 A1 and EP 0580541 A1 disclose benzimidazole compounds with selective H1 antihistaminic activity and devoid of arrhythmogenic effects. Patent application EP14382576.8 also discloses benzimidazole compounds having potent selective H1 antihistaminic activity, lacking activity on the central nervous system and on the cardiovascular system.
A particular compound with the above properties is 2-[4-(2-{4-[1-(2-Ethoxyethyl)-1H-benzimidazol-2-yl]-1-piperidinyl}ethyl)phenyl]-2-methylpropanoic acid, also known as bilastine, having formula:
and developed by Faes Farma, Spain, is a H1 antagonist benzimidazole compound with no sedative side effects, no cardiotoxic effects, and no hepatic metabolism. In addition, bilastine has proved to be effective for the symptomatic treatment of allergic rhinoconjunctivitis and urticaria.
The above benzimidazole compounds with selective H1 antihistaminic activity present low solubility in water, which impedes the development of pharmaceutically acceptable means of administering said compounds in liquid form. For example, the solubility of bilastine in the pH range 5-8 is around 500 μg/mL.
Therefore, there is a need in the art to provide a method for improving the solubility in water of said benzimidazole compounds with selective H1 antihistaminic activity. The present invention addresses such concern.
The applicant has surprisingly found that organic carboxylic acids selected from the group consisting of substituted or unsubstituted aliphatic C3-C8 α,ω-dicarboxylic acids and substituted or unsubstituted aliphatic C2-C6 monocarboxylic acids highly improve the aqueous solubility of bilastine. Particularly, it has been found that such organic carboxylic acids allow obtaining an aqueous solubility of bilastine above the pH-dependent solubility. Supersaturated aqueous solutions of bilastine can be obtained wherein the solubility is maintained over time.
Therefore, in a first aspect the invention is directed to a supersaturated aqueous solution of bilastine, comprising an organic carboxylic acid selected from glutaric acid, citric acid, α-cetoglutaric acid, tartaric acid, acetic acid, propionic acid and mixtures thereof.
In another aspect, the invention refers to the use of an organic carboxylic acid selected from glutaric acid, citric acid, α-cetoglutaric acid, tartaric acid, acetic acid, propionic acid and mixtures thereof to increase the aqueous solubility of bilastine as defined above.
In a further aspect, the invention is directed to a method for preparing a supersaturated aqueous solution of bilastine comprising
In another aspect, the invention is directed to a method for preparing a supersaturated aqueous solution of bilastine comprising
In a further aspect, the invention refers to a pharmaceutical composition comprising a supersaturated aqueous solution of bilastine and at least one pharmaceutically acceptable excipient.
In another aspect, the invention refers to the supersaturated aqueous solution or the pharmaceutical composition described herein for use as a medicament. Preferably, for use in the treatment or prevention of a disorder or disease susceptible to amelioration by antagonism of H1 histamine receptor such as allergic disease or disorder.
Another aspect of this invention refers to the supersaturated aqueous solution or the pharmaceutical composition described herein for use in the prevention and/or treatment of an allergic disease or disorder, such as rhinitis, conjunctivitis, rhinoconjuntivitis, dermatitis, urticarial and asthma.
Bilastine presents a pH-dependent solubility in water.
Within the scope of the invention, the term “saturated solution” means a solution containing a concentration of bilastine that is equal to the maximum amount of bilastine that can be dissolved at a specific temperature, typically set at 20° C., and pH (the so-called “saturation concentration”).
The term “supersaturated” solution means a solution that has a concentration of bilastine greater than the one that would be present in a saturated solution of bilastine at a specific temperature and pH. That is, a supersaturated solution is a solution containing a concentration of bilastine that is higher than its saturation concentration and wherein the full amount of bilastine is still completely dissolved. Therefore, a supersaturated aqueous solution of bilastine and an organic carboxylic acid as defined herein means an aqueous solution that has a concentration of bilastine greater than the one that would be present in a saturated aqueous solution of bilastine at a given temperature, typically 20° C., and pH.
Bilastine presents a pH-dependent solubility. Therefore, the supersaturated aqueous solution of the invention allows solubilizing an amount of bilastine that is above its pH-dependent solubility.
Supersaturated solutions are expected to be thermodynamically unstable leading to precipitation or crystallization of bilastine. However, it has been surprisingly found that the solubility of bilastine in the supersaturated aqueous solutions of the invention is maintained over time. They are stable supersaturated solutions.
In a particular embodiment, the supersaturated aqueous solution of the invention is stable for at least 12 h, preferably for at least 24 h under standard ambient conditions. This can be determined, for example, by measuring the solubility of bilastine by HPLC after said time.
The term “alkyl” refers to a linear or branched saturated hydrocarbon chain radical consisting of carbon and hydrogen atoms and which is attached to the rest of the molecule by a single bond. Particularly, the term “C1-6 alkyl” refers to an alkyl having between 1 and 6 carbon atoms. The term “C1-3 alkyl” refers to an alkyl having 1, 2 or 3 carbon atoms. Alkyl groups include for example and in a non-limiting sense, methyl, ethyl, n-propyl, i-propyl, n-butyl, t-butyl, n-pentyl, etc. Preferably “alkyl” refers to methyl or ethyl.
As understood in this technical area, there can be a certain degree of substitution on the previously defined radicals. The references to substituted groups indicate that the specified radical can be substituted in one or more available positions by one or more substituents.
The aqueous pharmaceutical composition of the invention comprises bilastine of formula,
This compound is 2-[4-(2-{4-[1-(2-Ethoxyethyl)-1H-benzimidazol-2-yl]-1-piperidinyl}ethyl)phenyl]-2-methylpropanoic acid, also known as bilastine. The synthesis of bilastine has been described in EP 0818454 A1.
The organic carboxylic acid according to the invention is selected from the group consisting of substituted or unsubstituted aliphatic C3-C8 α,ω-dicarboxylic acids and substituted or unsubstituted aliphatic C1-C6 carboxylic acids.
“Aliphatic C3-C8 α,ω-dicarboxylic acid” refers to an organic compound containing two carboxyl functional groups at the two ends of a C3-C8 saturated or unsaturated aliphatic chain, preferably a C4-C6 saturated or unsaturated aliphatic chain (“aliphatic C4-C6 α,ω-dicarboxylic acid”). That is, it is a compound of formula HOOC—R′—COOH, wherein R′ is the saturated or unsaturated C1-C6, preferably a C2-C4, aliphatic chain. Preferably the R′ group is a saturated chain.
In a particular embodiment, the R′ group is an unsubstituted saturated chain, that is R′ is —(CH2)n— wherein n is 1, 2, 3, 4, 5 or 6, preferably n is 2, 3 or 4.
The aliphatic C3-C8 α,ω-dicarboxylic acids can be substituted or unsubstituted. The substituents may be selected from the group consisting of —OH, —COOH and ═O. Preferably, the aliphatic C3-C8 α,ω-dicarboxylic acid has one, two or three substituents selected from —OH, —COOH and ═O, more preferably one or two.
In an embodiment, the aliphatic C3-C8 α,ω-dicarboxylic acid is an aliphatic C4 α,ω-dicarboxylic acid, aliphatic C5 α,ω-dicarboxylic acid, aliphatic C6 α,ω-dicarboxylic acid or an aliphatic C7 α,ω-dicarboxylic acid.
In a particular embodiment, the aliphatic C3-C8 α,ω-dicarboxylic acid is selected from glutaric acid, citric acid, α-cetoglutaric acid, tartaric acid, malic acid, adipic acid and succinic acid. Preferably, it is selected from glutaric acid, citric acid, tartaric acid and α-cetoglutaric acid. More preferably, it is glutaric acid.
The term “aliphatic C2-C6 monocarboxylic acid” refers to a saturated or unsaturated aliphatic chain containing one carboxyl functional group. The carboxyl functional group is preferably present at one end of the chain, having a molecular formula of R″—COOH, wherein R″ is a saturated or unsaturated C1-C5 aliphatic chain. Preferably the R″ group is a saturated chain, i.e R″ is a substituted or unsubstituted C1-C5 alkyl group.
In a particular embodiment, the R″ group is an unsubstituted saturated chain, that is R′ is an unsubstituted C1-C5 alkyl group, preferably an unsubstituted C1-C3 alkyl group.
The aliphatic C2-C6 monocarboxylic acids can be substituted or unsubstituted. The substituents may be selected from the groups consisting of —OH, —COOH and ═O. Preferably, the aliphatic C2-C6 monocarboxylic acid has one, two or three substituents selected from —OH, —COOH and ═O, more preferably one or two.
In an embodiment, the aliphatic C2-C6 monocarboxylic acid is an aliphatic C2 monocarboxylic acid, aliphatic C3 monocarboxylic acid or aliphatic C4 monocarboxylic acid.
In a particular embodiment, the aliphatic C2-C6 monocarboxylic acid is selected from substituted or unsubstituted acetic acid and propionic acid. Preferably, it is selected from acetic acid and propionic acid.
One aspect of the invention is directed to a supersaturated aqueous solution of bilastine, comprising an organic carboxylic acid selected from glutaric acid, citric acid, α-cetoglutaric acid, tartaric acid, malic acid, adipic acid, succinic acid, acetic acid, propionic acid and mixtures thereof. In another embodiment, the organic carboxylic acid is selected from glutaric acid, citric acid, tartaric acid, α-cetoglutaric acid, acetic acid, propionic acid and mixtures thereof. In a further embodiment, the organic carboxylic acid is selected from glutaric acid, citric acid, tartaric acid and mixtures thereof. Preferably, the organic carboxylic acid is glutaric acid.
In a particular embodiment, the supersaturated aqueous solution of the invention has a pH between 3 and 6, preferably between 3.5 and 5, more preferably between 4 and 4.5.
In a particular embodiment, the organic carboxylic acid is present in an amount so that the supersaturated aqueous solution has a pH of 3-6, preferably 3.5-5, more preferably 4-4.5.
In a particular embodiment, the molar ratio of bilastine:organic carboxylic acid is from 1:0.2 to 1:3, preferably from 1:0.3 to 1:2.5, more preferably from 1:0.5 to 1:2.
In a particular embodiment, the concentration of bilastine in the supersaturated solution of the invention is at least 1.3 times, preferably at least 1.5 times, more preferably at least 2 times, the concentration of bilastine in the saturated solution.
In an embodiment, the concentration of bilastine is at least 2.5 mg/ml, preferably at least 3.5 mg/ml, more preferably at least 4.5 mg/ml, at room temperature.
In an embodiment, the concentration of bilastine is at least 2.5 mg/ml at room temperature and a pH value higher than or equal to 4.2.
In another embodiment, the concentration of bilastine is at least 3.5 mg/ml at room temperature and a pH value higher than or equal to 4.2.
In a further embodiment, the concentration of bilastine is at least 2.5 mg/ml at room temperature and a pH between 4.2 and 4.4.
As used herein, “room temperature” or its abbreviation “rt” is taken to mean between 20 to 25° C. “Standard ambient conditions of temperature and pressure” or “standard ambient conditions” mean a temperature of about 20 to 25° C. and an absolute pressure of about 1 atm.
In a particular embodiment, the supersaturated aqueous solution is substantially free of further solubilizing agents, such as cyclodextrins, water-soluble polymers. The term “substantially free” means that the solution contains less than 1 wt. %, preferably less than 0.5 wt. %, more preferably less than 1000 ppm, of further solubilizing agents.
As mentioned above, it has been observed that organic carboxylic acids as disclosed above allow obtaining stable supersaturated aqueous solutions of bilastine. Therefore, in one embodiment, the invention is directed to the use of an organic carboxylic acid selected from the group consisting of substituted or unsubstituted aliphatic C3-C8 α,ω-dicarboxylic acids and substituted or unsubstituted aliphatic C2-C6 monocarboxylic acids and mixtures thereof as defined above to increase the aqueous solubility of bilastine as defined above.
In a particular embodiment, the invention is directed to the use of an organic carboxylic acid selected from the group consisting of substituted or unsubstituted aliphatic C3-C8 α,ω-dicarboxylic acids and substituted or unsubstituted aliphatic C2-C6 monocarboxylic acids and mixtures thereof as defined above to prepare a supersaturated aqueous solution of bilastine as defined above.
In another aspect, the invention is directed to the use of organic carboxylic acid selected from glutaric acid, citric acid, α-cetoglutaric acid, tartaric acid, acetic acid, propionic acid and mixtures thereof as defined above to prepare a supersaturated aqueous solution of bilastine as defined above.
In a particular embodiment, a supersaturated aqueous solution of bilastine as defined herein can be prepared by a process comprising:
In a particular embodiment, the slurry of step (a) has a pH between 3 and 6, preferably between 3.5 and 5, more preferably between 4 and 4.5.
In a particular embodiment, the organic carboxylic acid of step (a) is present in an amount so that the supersaturated aqueous solution has a pH of 3-6, preferably 3.5-5, more preferably 4-4.5.
In a particular embodiment, the slurry of step (a) comprises a molar ratio of bilastine:organic carboxylic acid from 1:0.2 to 1:3, preferably from 1:0.3 to 1:2.5, more preferably from 1:0.5 to 1:2.
Optionally, the process may include a step of filtration after step (b).
In another aspect, a supersaturated aqueous solution of bilastine as defined herein can be prepared by a process comprising:
In a particular embodiment, the slurry of step (a) comprises a molar ratio of bilastine:organic carboxylic acid from 1:0.2 to 1:3, preferably from 1:0.3 to 1:2.5, more preferably from 1:0.5 to 1:2.
In yet another particular embodiment, the slurry of step (a) is at a pH between 3 and 6, preferably between 3.5 and 5, more preferably between 4 and 4.5.
In step (b), the slurry is heated preferably until a solution is obtained. That is until bilastine is completely dissolved. In a particular embodiment, heating in step (b) refers to at least 60° C., at least 65° C., at least 70° C., at least 75° C., at least 80° C., at least 85° C. or at least 90° C. In a particular embodiment, heating in step (b) is between 60 and 100° C., preferably between 70 and 100° C., more preferably between 80 and 100° C.
The composition obtained in step (b) is then cooled to form a supersaturated solution of bilastine. Preferably, it is cooled to room temperature. In a particular embodiment, it is cooled slowly to room temperature, preferably over 2-10 h, more preferably over 3-6 h.
Optionally, the process may include a step of filtration step between step (b) and step (c).
In another aspect of the invention, a supersaturated aqueous solution of bilastine as defined herein can be prepared by a process comprising:
The co-crystal of step (a) can be prepared by techniques well-known in the art for the preparation of co-crystals. For instance, the co-crystal can be prepared by slurrying and by wet grinding (liquid or solvent assisted grinding).
In an embodiment, the co-crystal can be prepared by a slurrying process comprising:
The step i) may be performed by mixing equimolar amounts of bilastine and the carboxylic acid, and slurrying the mixture in the appropriate solvent. In a preferred embodiment the solvent is water. Step ii) is performed only when the slurry of step i) presents a temperature higher than room temperature. The obtained solid suspended in the solvent is isolated in step iii). The isolation of the solid may include, for example, one or more of the following operations: filtration, filtration under vacuum, evaporation, decantation, and centrifugation and other suitable techniques as known to a skilled person in the art. The cocrystal may be purified, e.g. by recrystallization.
In an embodiment, the co-crystal can be prepared by a liquid assisted grinding process comprising:
The grinding may be performed, for instance, in a ball mill. In a preferred embodiment the solvent is present in catalytic amount. The isolation of the solid may include, for example, one or more of the following operations: filtration, filtration under vacuum, evaporation, decantation, and centrifugation and other suitable techniques as known to a skilled person in the art. The cocrystal may be further purified, e.g. by recrystallization.
“Appropriate solvent” as used herein means a solvent or mixture of solvents selected from the group consisting of water, acetonitrile, dimethylsulfoxide, methanol, ethanol, isopropyl alcohol, ethyl acetate, isobutyl acetate, acetone, methyl isobutyl ketone, tetrahydrofurane, dioxane, diethylether, methyl tert-butyl ether, dichloromethane, chloroform, toluene, cyclohexane, xylene, heptane, dimethylformamide and N-methyl-2-pyrrolidone, preferably water, acetonitrile, methanol, ethanol and chloroform. In a particular embodiment the solvent is water or a mixture of water and other of the above mentioned “appropriate solvents”. In another embodiment the solvent is ethanol or a mixture of ethanol and other of the above mentioned “appropriate solvents”.
Other processes for obtaining the cocrystals known in the art may be used, such as for example, evaporation, crystallization by cooling, and heating-melting.
The process for preparing a cocrystal comprises putting in contact at least the first neutral component bilastine and a second neutral cocrystal forming compound. Without wishing to be bound by any particular theory, the process is such that it is believed that the first neutral component bilastine can either exist as a neutral zwitterionic species, wherein the acidic moiety is deprotonated and, simultaneously, the pyridinic nitrogen of the benzimidazole moiety is protonated or, as a neutral species, in which both acidic and benzimidazole moieties are neutral. In either case, the net charge of bilastine in the process of the invention is zero and thus the first component of the cocrystal is indeed neutral. Furthermore, the conditions are such that the cocrystal forming component is neutral and thus believed to lack any charges due to the pKa difference between the two cocrystal components. Therefore, the cocrystal forming component does not form ionic interactions with other molecules. As will be apparent to the skilled person, if the solvent is water, the pH is such that there is no deprotonation of the second cocrystal forming compound while if the solvent is an organic solvent, then there are no species responsible for deprotonating the second cocrystal forming compound.
In one embodiment the cocrystal comprises bilastine and glutaric acid. In a particular embodiment the molar ratio of bilastine:glutaric acid is 1:1. In a particular embodiment the molar ratio of bilastine:glutaric acid is 2:1. In another particular embodiment the cocrystal of bilastine and glutaric acid contains water molecules, i.e. it is a hydrate. In an embodiment the molar ratio bilastine:glutaric acid:water in said hydrate is between 2:1:3 and 2:1:1.
In a particular embodiment it is a cocrystal of bilastine:glutaric acid in a 2:1 molar ratio, named GL(I), having a X-ray powder diffraction pattern showing characteristic peaks at a reflection angle [2Θ in degrees] as disclosed in Table 3.1±0.2°.
In a particular embodiment it is a cocrystal of bilastine:glutaric acid in a 2:1 molar ratio, named GL(IV), having a X-ray powder diffraction pattern showing characteristic peaks at a reflection angle [2Θ in degrees] as disclosed in Table 3.3±0.2°.
In a particular embodiment it is a cocrystal of bilastine and glutaric acid in a 1:1 molar ratio, named GL(V), having a X-ray powder diffraction pattern showing characteristic peaks at a reflection angle [2Θ in degrees] as disclosed in Table 3.5±0.2°.
In another aspect, the invention refers to a pharmaceutical composition comprising as supersaturated aqueous solution of bilastine as defined herein and a pharmaceutically acceptable excipient.
The term “pharmaceutically acceptable excipient” refers to a vehicle, diluent, carrier or adjuvant that is administered with the active ingredient. Such pharmaceutical excipients can be sterile liquids, such as water and oils, including those of petroleum, animal, vegetable, or synthetic origin, such as peanut oil, soybean oil, mineral oil, sesame oil, and similar. Water or saline aqueous solutions and aqueous dextrose and glycerol solutions, particularly for injectable solutions, are preferably used as vehicles. Suitable pharmaceutical vehicles are described in “Remington's Pharmaceutical Sciences” by E. W. Martin, 21st Edition, 2005.
In an embodiment, the pharmaceutical composition is for oral or parenteral administration.
The excipients and auxiliary substances necessary to manufacture the desired pharmaceutical form of administration of the pharmaceutical composition of the invention will depend, among other factors, on the elected administration pharmaceutical form. Said pharmaceutical forms of administration of the pharmaceutical composition will be manufactured according to conventional methods known by the skilled person in the art. A review of different active ingredient administration methods, excipients to be used and processes for producing them can be found in “Tratado de Farmacia Galénica”, C. Faulí i Trillo, Luzán 5, S.A. de Ediciones, 1993.
Benzimidazole compounds have been found to be antagonists of histamine H1 receptor and are thus useful in the treatment and/or prevention of diseases known to be susceptible to improvement by antagonism of histamine H1 receptor.
Therefore, an aspect of the invention refers to a supersaturated aqueous solution or to a pharmaceutical composition as defined above for use in the treatment and/or prevention of a disorder or disease susceptible to amelioration by antagonism of H1 histamine receptor. Such diseases are, for example, allergic diseases or disorders.
In another aspect, the invention is directed to a supersaturated aqueous solution or to a pharmaceutical composition as defined above for use in the treatment and/or prevention of an allergic disease or disorder. Preferably, an allergic disease or disorder selected from rhinitis, conjunctivitis, rhinoconjunctivitis, dermatitis, urticaria and asthma. Preferably, an allergic disease or disorder selected from rhinitis, conjunctivitis, rhinoconjunctivitis and asthma. More preferably, the allergic disease or disorder is selected from the group consisting of rhinitis, conjunctivitis and rhinoconjunctivitis.
The term “treatment” or “to treat” in the context of this specification means administration of a compound or formulation according to the invention to ameliorate or eliminate the disease or one or more symptoms associated with said disease. “Treatment” also encompasses ameliorating or eliminating the physiological sequelae of the disease. The term “ameliorate” in the context of this invention is understood as meaning any improvement on the situation of the patient treated.
The term “prevention” or “to prevent” in the context of this specification means administration of a compound or formulation according to the invention to reduce the risk of acquiring or developing the disease or one or more symptoms associated with said disease.
The following examples illustrate the invention and should not be considered as limitative of the invention.
The following materials have been used: bilastine (suministered by FAES Farma), citric acid (Sigma-Aldrich), DL-tartaric acid (Sigma Aldrich), Hydrochloric acid (Pan reac).
HPLC analyses were performed by duplicate on an Agilent 1100 series apparatus with a XBridge C-18 column at room temperature. 25 μL sample were injected. The mobile phase (isocratic) was set as following: 52% (Methanol:aqueous octylamine 0.01M pH=7, 65:35)−42% (Acetonitrile:aqueous octylamine 0.01M pH=7, 60:40).
HPLC-PDA analysis was carried out using a Acquity BEH C18 1.7 μm 100×2.1 mm column at a temperature of 40° C. The isocratic mobile phase was composed of acetonitrile/methanol/ammonium bicarbonate 10 mM pH 8.7 (20.2/24.8/55.0%) (% v/v), at a flow rate of 0.6 mL/min. Samples were centrifuged 10 minutes at 4000 rpm at 20° C., and supernatant diluted to approx. 20-40 μg/mL in water. These diluted samples were kept at 18° C. until analysis. Quantization was performed at 220 nm by area comparison against a calibration curve obtained with bilastine working standard.
The grinding experiments were performed in a Retsch MM400 Ball Mill. The mixtures and the milling balls (stainless steel, diameter: 5 mm) were introduced in 9 position milling jars (stainless steel, cell volume: 1.5 mL), the solvent was added to each mixture with a 10 μL microsyringe and the jars were immediately introduced in the clamping device. The samples were then subjected to a 30 min grinding cycle (frequency: 30 s−1).
Sample preparation: the non-manipulated samples were mounted on a zero-background silicon holder. Data collection: Diffraction measurements were performed at ambient conditions on a PANalytical X'Pert PRO diffractometer with reflection θ-θ geometry, equipped with Cu K-alpha radiation and a PIXcel detector, operated at 45 kV and 40 mA. The samples were allowed to spin at 0.25 rev/s during the data collection. The measurement angular range was 3.0-40.0° (2θ) with a step size of 0.013°. The scanning speed was 0.3283°/s (10.20 s/step). Programs used: data collection with X'Pert Data Collector v 2.2i and treatment with X'Pert HighScore v 2.2c and X'Pert Data Viewer 1.2d.
Thermogravimetric analyses were recorded in a TA SDT Q600. Samples of 5 mg were weighed (using a microscale AE240, Mettler) into 90 μL open alumina crucibles, and were heated at 10° C./min between 25 and 300° C., under a nitrogen flow (50 mL/min). Data collection and evaluation was performed with TA Universal Analysis 2000 v 4.7 software.
Proton nuclear magnetic resonance analyses were recorded in various deuterated solvents, such as dimethylsulfoxide (DMSO-d6), methanol (MeOH-d4) and water (D2O) in a Varian Mercury 400 spectrometer. Spectra were acquired solving 5-10 mg of sample in 0.6 mL of deuterated solvent.
Solubility of cocrystals was determined by stirring the product in water at room temperature (400 mg of product in 24 ml of water, 60 vol.). The product was previously milled in order to reduce the crystal size effect. A sample is collected and filtered using a sintered funnel (n° 3) periodically (30, 60, 180 min and after overnight). The filtered solid was immediately analyzed by XRPD, while the mother liquors are filtered through a 0.22 um filter. The concentration of bilastine in the solution was determined by the first method for determining the solubility described above by HPLC analysis. The concentration of Bilastine is determined by HPLC area (in some experiments where a high solubility was detected the mother liquor was diluted by a factor 10). This concentration is compared with the bilastine concentration obtained in the same conditions in order to determine a relative solubility.
As used herein, “room temperature” or its abbreviation “rt” is taken to mean between 20 to 25° C. “Standard ambient conditions of temperature and pressure” or “standard ambient conditions” mean a temperature of about 20 to 25° C. and an absolute pressure of about 1 atm.
Method 1. A slurry of bilastine (120 mg) and the organic carboxylic acid (0.5-2.0 eq.) in water (15 ml) was prepared. The mixture was stirred at room temperature (25° C.) and centrifuged. The concentration of bilastine in the solution was determined by the first method for determining the solubility described above by HPLC analysis.
Slurrying bilastine and glutaric acid (0.5 eq.) gave rise to an elevated solubility (41000 area counts) after one night.
When the pH of a slurry of bilastine was adjusted with HCl to the same pH, a solubility of bilastine of only 28000 area counts was obtained after one night.
Method 2. A slurry of bilastine (100 mg) and the organic carboxylic acid (amount needed to obtain a pH of 4.0-4.5) in water (10 ml) was prepared. The mixture was stirred at 95° C. for 2 h and filtered. The filtrate was cooled to room temperature and allowed to stand overnight. After centrifugation, the concentration of bilastine in the solution was determined by the alternative method for determining the solubility described above by HPLC-PDA analysis.
Citric acid was added to a slurry of 100 mg of bilastine in 10 mL of water to get a pH of 4.3 and the mixture was heated at 95° C. for 2 h. Then the solid was filtered off and the filtrate was allowed to stand overnight at room temperature. The solid was separated by centrifugation and the concentration of bilastine was determined by HPLC-PDA.
D,L-Tartaric acid was added to a slurry of 100 mg of bilastine in 10 mL of water to get a pH of 4.3 and the mixture was heated at 95° C. for 2 h. Then the solid was filtered off and the filtrate was allowed to stand overnight at room temperature. The solid was separated by centrifugation and the concentration of bilastine was determined by HPLC-PDA.
Hydrochloric acid 3.7% v/v was added to a slurry of 100 mg of bilastine in 10 mL of water to get a pH of 4.3 and the mixture was heated at 95° C. for 2 h. Then the solid was filtered off and the filtrate was allowed to stand overnight at room temperature. The solid was separated by centrifugation and the concentration of bilastine was determined by HPLC-PDA.
Similar results were obtained for citric acid and tartaric acid. A solubility of 2.7 mg/ml of bilastine at pH 4.3 was observed for both citric acid and tartaric acid, which is clearly above the pH-dependent solubility of bilastine shown in
The crystalline form, named as GO), was obtained by wet grinding of a bilastine:glutaric acid 1:2 mixture in water.
This crystalline form was also obtained by slurrying bilastine and glutaric acid at a stoichiometry ratio of 1:1 or 1:2 in water. After stirring 15 hours, the obtained solid suspended in the water was isolated by filtration, washed with water and dried under vacuum.
This crystalline form was also obtained by seeding with GL(I) a suspension of BLN(I) (1000 mg, 2.157 mmol) and glutaric acid (570.0 mg, 4.314 mmol) in water (10 mL), at rt. After stirring 18 hours at rt, the obtained solid suspended in water was isolated by filtration, washed with water (2×1 mL) and dried under vacuum over 18 hours, to yield 974 mg of GL(I) as a white solid (yield 81%).
The resulting cocrystal was characterised by XPRD (see
Dissolution of cocrystal GL(I) in water gave rise to a solubility of 48000 area counts (see
This crystalline form was obtained by slurrying bilastine and glutaric acid at a stoichiometry ratio of 1:1, 1:2 or 2:1 in ethanol. After stirring for 15 hours, the obtained solid suspended in ethanol was isolated by filtration, washed with ethanol and dried under vacuum.
This crystalline form was also obtained by seeding with GL(IV) a suspension of BLN(I) (1000 mg, 2.157 mmol) and glutaric acid (285.0 mg, 2.157 mmol) in EtOH (10 mL), at rt. After stirring 18 hours at rt, the obtained solid suspended in water was isolated by filtration, washed with water (2×1 mL) and dried under vacuum over 18 hours, to yield 1.079 mg of GL(IV) as a white solid (yield 94%).
The resulting cocrystal was characterised by XPRD (see
Dissolution of cocrystal GL(IV) in water gave rise to a solubility of around 60000 area counts as shown in
This crystalline form was obtained by slurrying bilastine and glutaric acid at a stoichiometry ratio of 1:2 in MIK, AcOiBu or TBME.
This crystalline form was also obtained by slurrying bilastine and glutaric acid at a stoichiometry ratio of 1:1 or 1:2 in TBME or ACN. After stirring 18 hours, the obtained solid suspended in the solvent was isolated by filtration, washed with the same solvent and dried under vacuum.
This crystalline form was also obtained by seeding with GL(V) a suspension of BLN(I) (1000 mg, 2.157 mmol) and glutaric acid (570.0 mg, 4.314 mmol) in ACN (10 mL), at rt. After stirring 18 hours, the obtained solid suspended in ACN was isolated by filtration, washed with ACN (2×1 mL) and dried under vacuum over 18 hours, to yield 1.157 mg of GL(V) as a white solid.
The resulting cocrystal was characterised by XPRD (see
Dissolution of cocrystal GL(V) in water gave rise to a solubility of 60000 area counts (see
| Number | Date | Country | Kind |
|---|---|---|---|
| 15382574.0 | Nov 2015 | EP | regional |
| Filing Document | Filing Date | Country | Kind |
|---|---|---|---|
| PCT/EP2016/078154 | 11/18/2016 | WO | 00 |
